Fundación Lucha contra el Sida

Discontinuation of dolutegravir, elvitegravir/cobicistat, and raltegravir due to neuropsychiatric toxicity in a prospective cohort

Liver stiffness regression after successful Hepatitis C treatment is independent of HIV coinfection.

Analysis of the costs and cost-effectiveness of the guidelines recommended by the 2018 GESIDA/Spanish National AIDS Plan for initial antiretroviral therapy in HIV-infected adults.

Health-related quality of life of people living with HIV infection in Spain: a gender perspective

Overdose of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in an HIV-1-infected subject with attempted suicide

Incidence of cervical high-grade squamous intraepithelial lesions in HIV-1-infected women with no history of cervical pathology: up to 17 years of follow-up.

Clinically relevant thresholds for ultrasensitive HIV drug resistance testing: a multi-country nested case-control study.

Aging and the evolution of comorbidities among HIV-positive individuals in a European cohort.